Hepatitis C

Hepatitis C features

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:HIV treatment update

• 

  Staying safe inside: HIV and hepatitis C health care in prison

  Policies on safer sex and needle exchange in UK prisons seem to have stalled. With a high and increasing prevalence of hepatitis C in our jails, and...

  From:HIV treatment update

• 

  Staying free of hepatitis C

  It's still not clear exactly how HIV-positive gay men are contracting hepatitis C through sex. Until we know with certainty, Derek Thaczuk asks, how can we avoid co-infection?...

  From:HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:HIV treatment update

• 

  The new epidemic: HIV and hepatitis C infection in gay men

  “I’m surprised there isn’t a greater sense of urgency about this in the community.” Those were the words of Dr Kevin Fenton of the US Centers for...

  From:HIV treatment update

• 

  Double trouble – how hepatitis C is on the increase in HIV-positive gay men

  Studies at CROI showed how hepatitis C is gaining ground, says Gus Cairns. ...

  From:HIV treatment update

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:HIV & AIDS treatment in practice

• 

  Viral hepatitis in low and middle-income settings

  Management of HIV and hepatitis B or C co-infection in resource-limited settings....

  From:HIV & AIDS treatment in practice

Hepatitis C in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From:In your own words

Hepatitis C news from aidsmap

• Common side-effects of hepatitis C protease inhibitors: clinical management advice published

  The addition of the protease inhibitors telaprevir or boceprevir to hepatitis C treatment regimens increases the risk of anaemia, according to a review article published in Liver International. The author also found that telaprevir treatment was associated with an increased ...

  20 January 2012 | Michael Carter

• Early guidance on use of hepatitis C protease inhibitors in HIV-co-infected patients

  Doctors in the US state of Maryland have issued preliminary guidance for the use of hepatitis C protease inhibitors by patients co-infected with HIV. Published in the online edition of Clinical Infectious Diseases, the provisional recommendations support use of ...

  29 December 2011 | Michael Carter

• Hepatitis C transmission via injecting drug use: look beyond needles and syringes

  Important insights into the continued spread of hepatitis C among injecting drug users are provided by two studies published in the online edition of the Journal of Infectious Diseases. An international team of investigators showed that infectious quantities of hepatitis ...

  04 November 2011 | Michael Carter

• Persistence of very low levels of virus increase risk of relapse after hepatitis C therapy

  The persistence of a low viral load during the first twelve weeks of hepatitis C therapy is associated with an increased risk of relapse after the completion of treatment, investigators report in the December 1st edition of Clinical Infectious ...

  04 November 2011 | Michael Carter

• Hepatitis C drug boceprevir achieves 70% viral suppression rate in HIV co-infected people within 24 weeks

  Interim results presented at the Infectious Diseases Society of America (IDSA) conference yesterday show that 70.5% of 98 patients with HIV and hepatitis C who took the hepatitis C protease inhibitor (PI) drug boceprevir (Victrelis), plus pegylated interferon and ribavirin ...

  22 October 2011 | Gus Cairns

• Gene variant that helps hepatitis C treatment may hinder HIV treatment

  A common variant in a gene that doubles the chance of hepatitis C treatment working in people co-infected with HIV may also nearly double the risk of death in patients taking antiretroviral therapy. A study from Poland found that ...

  14 October 2011 | Gus Cairns

• New anti-hepatitis C drug BMS-790052 does well in Phase IIa study

  Up to 83% of individuals with chronic hepatitis C virus achieved a sustained virological response after receiving the investigational drug BMS-790052 in combination with pegylated interferon and ribavirin, results of a study presented to the 51st Interscience Conference on ...

  20 September 2011 | Michael Carter

• Coffee consumption reduces side-effects in people on hepatitis C treatment

  Drinking three or more cups of coffee a day reduced the incidence of self-reported side-effects by more than 80% compared to non-coffee drinkers in people co-infected with hepatitis C and HIV who were taking hepatitis C treatment, a French study ...

  14 September 2011 | Gus Cairns

• Some rapid hepatitis C tests have high false-negative rate in people with HIV

  Approximately 9% of hepatitis C infections in HIV-positive individuals are missed by some rapid hepatitis C testing assays, US investigators report in the September 15th edition of the Journal of Infectious Diseases. Three rapid tests were evaluated in the ...

  22 August 2011 | Michael Carter

• Boceprevir response and resistance differs according to HCV genotype 1 subtype

  People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported last week at the International AIDS ...

  28 July 2011 | Liz Highleyman

More news

Hepatitis C news selected from other sources

• European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People

  People who are already HIV positive when they acquire hepatitis C virus (HCV) may not experience unusually rapid liver disease progression over the long term, even though the fibrosis progression rate may appear high during the acute stage of infection, according to a European FibroScan study described in the February 15, 2012, issue of Clinical Infectious Diseases.

  02 February 2012 | HIVandHepatitis.com

• More must be done to reduce hepatitis C transmission amongst HIV positive gay men

  The rate of HIV-positive gay men co-infected with hepatitis C in the UK is too high. It is crucial for this to be addressed as a strategic priority in gay men's health promotion. 

  30 January 2012 | NAT

• Entry Point for Hepatitis C Infection Identified

  A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

  25 January 2012 | University of Illinois press release

• Hepatitis C vaccine: Oxford researchers' trial 'promising'

  An early clinical trial of a hepatitis C vaccine has shown "promising" results, according to researchers at Oxford University.

  04 January 2012 | BBC

• Top 10 HIV and Hepatitis Stories of 2011

  In our last issue for 2011, HIVandHepatitis.com reviews some the year's major news highlights.

  03 January 2012 | HIVandHepatitis.com

• AASLD: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV

  The hepatitis C virus (HCV) NS3/4A protease inhibitor danoprevir (formerly RG7128) plus pegylated interferon/ribavirin produced high cure rates and many patients were eligible for shorter therapy, according to findings presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.

  12 December 2011 | HIVandHepatitis.com

• Poor Liver Transplant Outcomes for HIV/HCV Coinfected Patients

  Patients coinfected with hepatitis C virus (HCV) and HIV have only a 55% chance of survival 5 years after liver transplantation, according to results from a study performed at a French transplant center.

  06 December 2011 | Medscape (requires free registration)

• AASLD: Upping Ribavirin Dose Does Not Increase Interferon Effectiveness in HIV/HCV Coinfected Patients

  Starting hepatitis C treatment with a double dose of ribavirin plus erythropoietin to manage anemia did not lead to higher rates of sustained response to interferon-based therapy in HIV/HCV coinfected people, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.

  24 November 2011 | HIVandHepatitis.com

• AASLD: Epidemic of Sexually Transmitted HCV among HIV+ Gay Men in Amsterdam Levels Off

  The epidemic of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV positive men who have sex with men (MSM) in Amsterdam appears to have stabilized since 2008-2009, but monitoring and prevention efforts are still needed.

  21 November 2011 | HIVandHepatitis.com

• Can simple blood tests predict liver cancer?

  FIB-4 could represent a relatively cheap and simple way of screening people with HBV, HCV and other risk factors for the possibility of liver cancer.

  18 November 2011 | CATIE

More news